Bergen, D., Kague, E., & Hammond, C. (2019). Zebrafish as an emerging model for osteoporosis: a primary testing platform for screening new osteoactive compounds. *Frontiers in Endocrinology, 10*, [6]. https://doi.org/10.3389/fendo.2019.00006
Zebrafish as an Emerging Model for Osteoporosis: A Primary Testing Platform for Screening New Osteo-Active Compounds

Dylan J. M. Bergen, Erika Kague and Chrissy L. Hammond*

1 School of Physiology, Pharmacology and Neuroscience, Biomedical Sciences Building, University of Bristol, Bristol, United Kingdom, 2 Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, Southmead Hospital, University of Bristol, Bristol, United Kingdom

OPEN ACCESS

INTRODUCTION

Osteoporosis is metabolic bone disease caused by an altered balance between bone anabolism and catabolism. This dysregulated balance is responsible for fragile bones that fracture easily after minor falls. With an aging population, the incidence is rising and as yet pharmaceutical options to restore this imbalance is limited, especially stimulating osteoblast bone-building activity. Excitingly, output from large genetic studies on people with high bone mass (HBM) cases and genome wide association studies (GWAS) on the population, yielded new insights into pathways containing osteo-anabolic players that have potential for drug target development. However, a bottleneck in development of new treatments targeting these putative osteo-anabolic genes is the lack of animal models for rapid and affordable testing to generate functional data and that simultaneously can be used as a compound testing platform. Zebrafish, a small teleost fish, are increasingly used in functional genomics and drug screening assays which resulted in new treatments in the clinic for other diseases. In this review we outline the zebrafish as a powerful model for osteoporosis research to validate potential therapeutic candidates, describe the tools and assays that can be used to study bone homeostasis, and affordable (semi-)high-throughput compound testing.

Keywords: zebrafish, screening, genetic mutants, osteoblast, osteoclast, osteoporosis, drug development, animal model
are coupled, anti-resorptives can negatively affect anabolic osteoblast activity and may not fully restore bone architecture (6). The only injectable osteoanabolic compound, teriparatide, is an analog of the parathyroid hormone (7). However, it is not an ideal long-term therapy option as, not only is it expensive, long term exposures in rat increase susceptibility to osteosarcoma (8, 9) limiting treatment duration (currently 2-years) in OP patients (10). Thus, an ideal treatment plan should focus on both strengthening bones using an osteoanabolic compound, combined with use of an anti-resorptive treatment (also ideally non-invasive) to maintain bone integrity (5), few such options exist. Currently, a major bottleneck in the development of new pharmaceuticals is the collection of primary functional data on new biological drug targets with osteo-anabolic capacities.

The twinning of genetic information with mechanistic data is key for development of new treatments. For example, familial studies on high bone mass (HBM) cases led to the discovery of mutations in SOST (Sclerostin). Further mechanistic data generated in model systems showed that SOST acts negatively on the WNT signaling pathway and led to the development of a novel antibody treatment Romosozumab (approved in 2018 for clinical use), which blocks SOST activity (11–13). With the advent of genome-wide association studies (GWAS), and efficient whole-genome/exome sequencing (WGS/WES) data mapping there has been a sizeable increase in availability of human genetic data from cohort studies for musculoskeletal conditions including OP, high bone mass (HBM), and osteoarthritis (OA) (14–20). Recent large cohort studies, such as UK-Biobank, have identified many new loci that contain novel osteogenic factors. For example, the UK-Biobank (21) data yielded 518 loci associated with changes in BMD using heel ultrasound data (16, 19). Currently, there is a substantial gap in translating these human genetic findings to model systems (22) in which the mechanism by which these genes act on the skeleton can be defined, where hypotheses can be tested, and ultimately define new putative drug targets that can be assessed with pharmacological agents. Because the skeletal system involves complex interactions between different cell and tissue types, genes and mechanical stimuli it is difficult to recapitulate features of OP in a petri dish. However, traditional rodent models are expensive to genetically manipulate. Zebrafish (Danio rerio) could therefore bridge this gap by offering fast genetic manipulation and complex tissue interactions required to model complex diseases such as OP.

Zebrafish are vertebrates and show strong similarities in their skeletal physiology to mammals (23). They are highly fecund and a single pair of fish can lay up to 300 eggs a week, which develop externally and are translucent (24). They show conservation of 70% of all genes and 85% of disease genes with humans (25, 26). However, the main advantage of zebrafish for functional genetic studies is their genetic tractability, as constructs that modify the genome can be injected directly into embryos at the single cell stage. This has allowed the generation of transgenic lines that allow dynamic imaging of all the cells of the developing skeletal system in live larvae (27–29) (Table 1) and in more recent years allowed genome editing strategies to be employed. In this review we set-out these different approaches and how developing adult zebrafish can be used to study bone mineralization, bone content formation, and osteoblast-osteoclast interactions in a whole animal context. We also discuss future prospects for drug screening pipelines in zebrafish which may confer advantages over other pre-clinical model systems.

**FLEXIBLE GENETIC MANIPULATION IN THE ZEBRAFISH**

Zebrafish are genetically high amenable and new ways to manipulate the genome are constantly being added to the zebrafish genetic toolbox, which includes knockout, knock-down and, DNA insertion strategies. The external development of the embryos allows tools targeting genes of interest to be microinjected directly in embryos at the 1-cell stage and hundreds of embryos can readily be injected in a morning. Acute knockdown of gene expression can be achieved either by targeting mRNA with antisense RNA morpholino (MO) molecules that stably bind the target mRNA to block translation or splicing through steric hindrance (41). MOs offer a rapid method to assess the phenotype of a gene of interest during early development. However, they can only be used to study developmental processes occurring over the first 4 or 5 days of development, which limits their utility in skeletal studies as mineralization occurs from 4 days of development. While concerns have been raised about MO veracity as morphants frequently show more severe phenotypes than stable mutants generated for the same gene (42, 43). This is due to a transcriptional compensation response for chronic loss of a gene as has been shown in mouse, cultured human cell lines, plants, and zebrafish models (44–51). Thus, while MOs have a role, their use has been largely supplanted by use of genome editing strategies.

Traditionally, zebrafish mutant lines have been generated by forward genetic screening; using mutagens [e.g., N-ethyl-N-nitroso urea (ENU)] to induce random point mutations in offspring that were then screened for phenotypes of interest (52–56). The expansion of the zebrafish genetic toolkit with zinc-finger nucleases (ZFN), Transcription Activator-Like Effector Nuclease (TALEN) (57, 58), and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 (59) reverse genetic strategies, which, in combination with a fully sequenced genome (25), allow tailored gene-specific mutagenesis in the zebrafish. Gene function can be studied in genetic knockouts by generating insertion/deletion (indel) mutations leading to premature stop codons, deleting whole exons containing important protein domains and generate new stable mutant lines (Figure 1A). Moreover, the CRISPR/Cas9 protocol is so efficient that the F0 injected fish (crispants) can be used to study loss of gene function in these crispants, despite them carrying mosaic mutations (i.e., not every cell carries a mutation and more than one mutation may be present) (23, 60) (Figure 1B). Single base gene editing (knock ins) using modified Cas9 enzymes or supplying a DNA template for the endogenous homologous recombination machinery initiated by a double stranded break allows to introduce specific genetic changes to
model specific human disease mutations in zebrafish orthologs (62, 63).

SIMPLE ASSESSMENT OF ZEBRAFISH BONES DURING DEVELOPMENT AND ADULTHOOD

Zebrafish in common with higher vertebrates, have both dermal/intramembranous ossification, in which bone is formed de novo directly by osteoblasts, and chondral/endochondral ossification in which bone forms by progressively replacing a cartilaginous template. Although zebrafish have thinner bones than terrestrial vertebrates, with fewer embedded osteocytes and little trabeculation, all of the relevant skeletal cell types and modes of regulation are conserved between zebrafish and higher vertebrates. This, importantly for the study of OP, includes osteoblast and osteoclast coupling and regulation of bone remodeling (64, 65).

A major advantage of using zebrafish to probe the mechanism of bone homeostasis is that cell behavior can be visualized dynamically in vivo. Zebrafish larvae are translucent and develop rapidly (24), and early skeletal processes can be dynamically visualized in the living fish through use of fluorescent transgenic reporter lines marking these cell types (see Table 1 for examples).

Formation of the craniofacial skeleton occurs early, with the first cartilaginous structures of the jaw forming by 2 days post fertilization (dpf) (66), the first skeletal joints are formed and mobile by 3 dpf (60), by 5 dpf, hypertrophic chondrocytes, marked by col10a1a, are seen in some elements from 5 dpf (29), and first osteoblasts surrounding the cartilage and forming bone matrix by 7 dpf (67). The first intramembranous bones, such as the cleithrum, anterior notochord, and operculum, are visible in the craniofacial skeleton from 72 hpf (66). While skeletal development occurs early, true remodeling through the combined activity of osteoblasts and osteoclasts does not commence until the second week of development as osteoclasts (marked by Cathepsin-K (Cisk) or TRAP) are not formed until day 10–12. Unlike mammals, mononucleated osteoclasts as well as multinucleated cells are present and actively resorb bone (65, 67).

There are many transgenic lines available to mark musculoskeletal tissues, these include reporter lines which label cells or signaling pathway activation by driving expression of proteins in the cytoplasm, targeted to the nucleus, or plasma membrane, and lines that tag proteins (28, 68). Reporter lines mark cell types by using a tissue specific promoter, responsive elements from a signaling pathway, or transcription factor binding sites controlling expression of a fluorescent protein (Table 1). For example, to study bone homeostasis, osteoblasts

### Table 1: Common transgenic lines to study musculoskeletal system in small teleostei.

| Gene/pathway | Cell type(s) | Description | Transgenic line | Citation |
|--------------|--------------|-------------|----------------|---------|
| BMP pathway | BMP transcriptionally activated cells | Reporter—21 BMP responsive elements (BMPRE) from X. laevis | Tg(SxBMPRE-Xla.Id3:GFP) | (50) |
| collagen10a1a | Osteoblasts (juvenile) | Reporter—BAC containing zebrafish collagen10a1a promoter | TgBAC(col10a1a:Citrine) | (29) |
| collagen2a1 | Chondrocytes | Reporter—BAC containing zebrafish collagen2a1 promoter | Tg(Col2a1aBAC:mCherry) | (29) |
| ctsk | Osteoclasts | Reporter—BAC containing zebrafish ctsk promoter | TgBAC(ctsk:Citrine) | (27) |
| entpd5a | Mineralizing osteoblasts | Reporter—BAC containing zebrafish entpd5a promoter | TgBAC(entpd5a:Citrine/YFP) | (27) |
| ffl1a | Vasculature/neural crest | Reporter—BAC containing fl1a promoter | Tg(ffl1a:EGFP) | (31) |
| Hedgehog pathway | Gli transcriptionally activated cells | Reporter—8 Gli responsive elements driving egfp or mCherry | Tg(Gli-d:egfp/mCherry) | (32) |
| Osteocalcin | Osteoblasts (mature) | Reporter—3.7 kb upstream osteocalcin promoter from Medaka driving gfp expression | Tg(Ola.osteocalcin:EGFP) | (33) |
| rankl | Osteoclast-osteoblast interaction | Conditional—Heat shock inducible (HSE) ubiquitous simultaneous expression of rankl and cfp in medaka | Tg(rankl:HSE:CFP) | (34) |
| runx2 | Osteoblasts (juvenile) forming new bone | Reporter—557 bp intronic human RUNX2 enhancer (Hsa), regulating RUNX2, conserved in multiple species, driving gfp expression | Tg(Hsa.RUNX2-Mmu.Fox:EGFP) | (33) |
| sox10 | Mesenchymal chondrocytes | Reporter—4.9 kb of sox10 promoter driving egfp | Tg(−4.9Sox10:EGFP) | (35) |
| sp7 (osx) | Osteoblasts | Reporter—BAC containing zebrafish sp7 promoter | Tg(sp7:EGFP) | (36) |
| sp7 (osx) | Osteoblasts | Reporter—Medaka sp7 regulatory elements driving nls-gfp or mCherry | Tg(sp7:nGFP/mCherry) or Tg(Ola.sp7:NLS:GFP) | (37) |
| sp7 (osx) | Osteoblasts | Reporter—BAC sp7 promoter driving luciferase expression | Tg(Ola.sp7:Luciferase) | (38) |
| sp7 (osx) | Osteoblasts (ablation) | Conditional—Chemical ablation of osteoblasts by E. coli enzyme Nitroreductase (NTRo) activity | TgjostericinCherry-NTRo:dp46 | (39) |
| WNT - β-catenin pathway | β-catenin activated cells | Reporter—T-cell factor enhancer (TCF) promoter containing 7 beta-catenin binding sites | Tg(7xTCFXXtSlam:nslGFP) | (40) |

BAC, bacterial artificial chromosome; bp, base pair; kb, kilobase.
FIGURE 1 | Rapid and efficient mutagenesis using CRISPR/Cas9 genome editing in zebrafish. **(A)** To generate a stable mutant line, F0 CRISPR/Cas9 injected individuals carrying mosaic mutations (defined by fin-clipping) should be outcrossed to wildtype fish to allow selection of a single germline mutation. Out-crossing the founder to wildtype will establish a stable F2 mutant line. Note that the F1 can have multiple founders with damaging mutations, incrossing these will result in F2 homozygotes (for recessive alleles) for functional analysis. When performing incrosses from F2, it will take another 2 months of breeding time. **(B)** This rapid protocol can be used to generate mutations in a gene of interest using CRISPR/Cas9 RNA or protein with gRNAs targeted against the gene from custom made gRNA oligos (i). Micro-injection of CRISPR/Cas9 RNA or protein and gRNAs specific to gene of interest into embryos at the single cell stage (ii) generating double stranded breaks during the first few rounds of cell divisions. The repair machinery is prone to errors and those cells will carry a different type of mutation giving a range of insertion and deletion (indel) mutations (spectrum of mutations, mosaicism). The overall mutagenic efficiency is typically high (around 80% with fragment analysis) allowing larval skeletal phenotypes to be assessed in the injected (F0) population (iii). After imaging an Alizarin Red S (AR) stained individual in a transgenic background (here osteoblast marker sp7:gfp)(iii), mutagenesis assessment such as fragment analysis will determine a quantified mutagenesis rate (iv) which can be correlated to a phenotype (iv). Note that mosaic mutants (crispants) can also be grown up to see the effect on the adult skeleton.
and osteoclasts can both be labeled in vivo, using osteoblast reporters such as sp7, and osteoclast reporters such as ctsk, so that their numbers, location and activity monitored in living bone tissue either longitudinally, in response to drug treatment, genetic mutation, or environmental stimuli (Table 1). Relevant to research into OP, osteoclasts can be specifically temporally activated by use of a heat shock promoter driving RANK ligand (rankl) expression; such that following a period of immersion in water at 39°C, osteoclast activity, labeled with the blue fluorescent protein (CFP), is increased resulting degradation of the bone matrix and in an osteoporotic phenotype of low BMD (34). A simple Alizarin Red S (AR) staining, which marks calcium phosphate crystals and fluoresces strongly in the red channel (580 nm wavelength), allows a rapid assessment of ossified elements in live or fixed fish. In combination with transgenic lines, endochondral ossification in the lower jaw (Figure 2A) and intramembranous bone formation in the operculum (Figure 2B) can be easily visualized compared to traditional rodent models.

IMAGING THE ADULT SKELETON FOR ASSESSING MINERALIZATION

The zebrafish adult skeleton is relatively complex and once fully formed by around 2 months is composed of 74 ossified cranial elements (compared with 22 in humans), 28–31 vertebrae; 4 cervical, 10–11 thoracic vertebrae, and 15–16 separated vertebrae in the tail region and fins (pectoral, dorsal, anal (ventral), and caudal) (69). As in larvae, live AR and Calcein staining, or use of transgenic lines, allows easy detection of superficially located calcified elements in the skull, elasmoid scales, and fins using a simple fluorescent microscope. Deeper tissues can be imaged by multiphoton microscopy in small juveniles. However, bones located more internally (e.g., vertebrae and ribs) in large adults are difficult to visualize using this method. Post-mortem staining of bone (AR) and cartilage [Alcian blue (AB)] is a cost-effective way to analyse these structures for adult skeletal abnormalities (Figure 3A) and has been used in forward genetic screens to obtain detailed skeletal morphology information (56, 70, 71).

Recent advances in X-ray based imaging: radiographs, micro-computed tomography (μCT), and synchrotron equipped μCT technologies (SR-μCT), and their subsequent downstream imaging processing, opened avenues to assess the adult zebrafish skeleton. The major advantage of using these X-ray imaging techniques is that they are non-destructive and can be used in the intact fish, allowing the samples to be used for other purposes, such as histology. Radiographs give two-dimensional (2D) images of the zebrafish skeleton at relatively low resolution (Figure 3B), permitting the visualization of bone elements and a broad evaluation of changes in the skeleton, radiographs can

---

**FIGURE 2** | Ossified elements in the cranial region during early development. (A) Ventral view of a 7 days live Alizarin Red S (AR) labeled larval jaw showing dermal ossification of cleithrum (CL), and ossification of the cartilaginous ceratohyal (CH). Arrow indicates the CH which undergoes endochondral ossification. Slow muscle transgene reporter in green (smych:gfp). Image taken on a Leica lightsheet microscope. (B) Lateral view of a 6 days old larva live labeled with Alizarin Red S (red) and carrying GFP under the control of the osteoblast promoter sp7/osterix (green; sp7:gfp) allowing visualization of mineralized elements (red) and osteoblasts (green) in a living individual. Insets show the cleithrum (i) and operculum (ii) with osteoblast enrichment at the distal ends of these elements (gray arrows). Image taken on a confocal microscope. Wildtype strains AB/TL in both panels. Ossified elements: BR, branchiostegal ray; CH, ceratohyal; CL, cleithrum; MC, Meckel’s cartilage; MX, maxilla; OP, operculum; PBC, posterior basicranial commissure; PQ, palatoquadrate. Scale bars = 100 μm.
be used to image live anesthetized fish permitting longitudinal analysis of the skeleton over time (70). Higher resolution (2 μm voxel size) and three-dimensional (3D) assessment of the zebrafish skeleton can be achieved by using μCT (Figures 3C–E). As fish bone, like that of mammals, is composed of hydroxyapatite crystals, quantification of BMD can be performed by comparison to phantoms, which are samples of known hydroxyapatite content (72). Additionally, treatment with agents to improve contrast such as silver nitrate (AgNO₃) or iodine, allow detection of juvenile (less dense) bone and of soft tissues such as muscle and cartilage (72).

Very detailed data on bone micro-architecture can be achieved with SR-μCT (73, 74). This technique can yield a spatial resolution of 100 nanometres on tissue samples and visualize fine bone structures at a cellular level including the vasculature in mineralized bone, osteoclast resorption pits, and osteocyte lacunae (75). As the size and resolution of data sets increase, the bottleneck in the process is frequently data analysis. Commercially available software packages such as “boneJ” are tailored for CT data analysis, and recently open source user friendly software have become available to process μCT data from zebrafish scans. For example, the “FishCut” software processes whole-body μCT scan datasets and applies semi-automated analysis algorithms. The current version segments the axial skeleton, then generates values for the surface area of vertebrae and centrae, and calculates BMD and mineralized thickness in a semi-automated fashion (76).

**ZEBRAFISH MUTANTS OF BRITTLE OR THIN BONES**

An increasing number of zebrafish genetic mutants in skeletally relevant genes have been shown to recapitulate human bone disease. These have provided insight into the dynamic regulation of bone formation, mineralization, and remodeling. We have included a list of zebrafish skeletal mutants in Table 2. While there are currently few models for OP, there are various zebrafish mutant lines that accurately model human skeletal dysplasias, including collagenopathies and forms of osteogenesis imperfecta, which are characterized by brittle bones and frequent low-impact bone fractures. Autosomal dominant mutations COL1A1 and COL1A2 genes predominantly affect glycine-X-Y (Gly-X-Y) repeat domains that result in collagen α1(I) and α2(I) heterotrimer maturation defects (119), causing fragile bone matrix and insufficient mineralization (120). The Gly-X-Y mutations lead to impaired hydroxylation and defects in collagen maturation in the endoplasmic reticulum (ER), which is also conserved in zebrafish (121–123). The autosomal dominant chinuhua (chi) zebrafish mutant, was identified in a forward genetic screen using radiography (70). Linkage mapping identified a mutation causing a glycine to aspartate amino acid substitution in a conserved Gly-X-Y repeat of col1a1a (zebrafish col1a1 is duplicated). Note that in contrast to mammals, zebrafish type-I collagen is constituted by three different α chains [α1 (col1a1a), α3 (col1a1b), α2 (col1a2)] due to duplication (124). chi/+ zebrafish display phenotypes resembling those seen in humans, including a shortened axial skeleton, with irregular radiodensity, uneven mineralization, and brittle bones that fracture easily (especially ribs). Transmission electron microscopy revealed that chi/+ fish show signs of ER stress (70). The ER trapping of insufficiently hydroxylated oligotrimerized α1(1)/α2(1)/α3(1) collagen leads to lower extra-cellular collagen maturity, abnormally shaped and thinner vertebrae bodies, areas of higher calcium content, different local mechanical properties, and reduced osteocyte number (84). Osteogenesis imperfecta has a broad disease spectrum in the clinic, and recent comparative studies of multiple mutant alleles for col1a1a, col1a1b, col1a2, and also bmp1a (described later) and plad2 described a diversity of skeletal phenotypes (Table 2) with brittle bones as the common feature (85).

The zebrafish sp7/osterix mutant has been shown to model human osteogenesis imperfecta caused by recessive damaging mutations in SP7 (125). This mutant showed uneven mineralization, severe fractures caused by minimal impact, and
### TABLE 2 | Zebrafish mutants, transgene insertion mutants, and morphants showing altered skeletal mineralization.

| Human gene | Zebrafish name | BMD effect | Primary defect/effect | Fish modeling | Human skeletal phenotype | Citation |
|------------|----------------|-------------|-----------------------|---------------|-------------------------|----------|
| ABCG6      | grate          | +           | ATP hydrolysis defects causing (ectopic) increased mineralization in spine and soft tissues | N/A           | Pseudoaxanthomelanosis   | (77)     |
| ATP6V1H    | atp6v1h       | –           | Increased osteoclast activity by upregulated mmp9 and mmp13 | Osteoporosis  | Familial osteoporosis with short stature | (78)     |
| BMP1       | frilly fins, welded | –           | Fibrillar collagen processing affecting bone matrix integrity | Osteogenesis imperfecta | Osteogenesis imperfecta (in vertebral bones but weak bones) | (72, 79, 80) |
| C-FMS (CSF1R/CD115) | panther, csfr1a | +           | Reduced osteoclast number and immune cell mobility causing stenosis | Osteoporosis  | N/A                     | (72, 81, 82) |
| COL1A2     | col1a2        | +           | Collagen triple helical stability; dominant effect | OA: Stickler syndrome | Stickler Syndrome | (63)     |
| COL1A1     | chihuahua, microwaved, dhh1, dhh14, dhh15, dhh29 | –           | Collagen triple helix stability; dominant effect leading to brittle bones in axial and fin skeleton | Osteogenesis imperfecta and Ehlers-Danlos syndrome (chihuahua and microwaved) | Osteogenesis imperfecta and Ehlers-Danlos Syndrome | (56, 70, 79, 84–86) |
| COL2A1     | dhh21 (?) , dhh27, dhh28, dhh30 (?) | =           | Collagen triple helical stability; dominant effect. Notochord and vertebral column deformations | Spinal deformations | Stickler syndrome | (58)     |
| CTSK       | ctsk *V       | +           | Depletion of pre and mature osteoclasts | Osteoporosis  | Osteoporosis | (87)     |
| CX43 (GJA1) | stoepsel, short-of-fin | – (?)       | Brittle vertebrae anomalies due to loss of paracrine function of hemichannel (Ca2) activity | N/A           | Ocular-dento-digital dysplasia | (88, 89) |
| CYP26B1    | stocksteif, dolphin, cyp26b1 | +           | Hyper-mineralization and fusion of the vertebral and joint cartilage due to altered intracellular retinoic acid metabolism | Retinoid acid processing | Craniosynostosis, craniofacial anomalies, fusions of long bones | (37, 90, 91) |
| DKK1 (DICKKOPF) | hs:dkk* | –           | When heat-shocked, Dkk1 is expressed and blocks Wnt/Beta-catenin signaling. Impaired elastoid scale and ray fin outgrowth. | N/A           | Osteolytic bone lesions in multiple myeloma patients | (92)     |
| EDA and EDAR | nakt (eds), finless (edar), fang (edar), topless (edar) | –           | Absence and deformation of dermal bone structures such as lepidotrichia, elastoid scales, and skull | Ectodermal dysplasia, impaired teeth | Hypohidrotic ectodermal dysplasia 1 (X-linked); Tooth agenesis | (93)     |
| ENPP1      | dragonfish    | +           | Ectopic hyper-mineralization in axial skeleton due to altered phosphate metabolism | Arterial calcification of infancy | Arterial calcification /hypophosphatemic rickets | (94, 95) |
| ENTPD5     | no bone       | –           | Does not mineralize bone due to altered phosphate metabolism | N/A           | N/A                     | (94)     |
| GBA1       | gba1          | –           | Impaired osteoblast differentiation due to altered Wnt signaling | Osteoporosis, Gaucher disease | Osteoporosis, Gaucher disease | (96)     |
| GLI2       | hs:gli2-DR*   | –           | Heat-shock (hs) initiates expression of dominant repressive Gli2. Impaired scale morphology | N/A           | Culler-Jones syndrome; holoprosencephaly | (92)     |
| GOLGB1 (giantin) | golgb1 | +           | Ectopic mineralization in spine and soft tissues by transcriptionally down regulating galnt3 and changed cilia morphology | N/A           | GOLGB1 unknown--GALNT3 mutations cause tumoral calcinosis | (49, 50) |
| IHH        | ihha          | –           | Loss of mineralization due to blocked osteoblast differentiation in endochondral bone. Irregular operculum and scale morphology with reduced AR stain | Endochondral bone repair and dermal ossification | Acrocapitofemoral Dysplasia, Brachydactyly Type A1 | (67, 97–99) |
| ITGA10     | itga10 ($)    | –           | Focal adhesion integrin A/B subunits. Downregulated in prednisolone larvae. | Osteoporosis  | N/A                     | (103)    |
| ITGBL1 #   | itgb1 ($)     | –           | Anti-adhesive integrin A/B subunits. Downregulated in prednisolone larvae. | Osteoporosis  | N/A                     | (103)    |

(Continued)
TABLE 2 | Continued

| Human gene | Zebrafish name | BMD effect | Primary defect/effect | Fish modeling | Human skeletal phenotype | Citation |
|------------|---------------|------------|----------------------|---------------|-------------------------|----------|
| LGMN | lgmn ($) | + | Legumain (secreted cysteine protease) inhibits osteoblast activity by degradation of fibronectin | Osteoporosis | Osteoporotic–upregulated in OP bone | (101) |
| LRP4 | lrp4 MO | – (?) | Malformed pectoral and tail fin and deformed craniofacial skeleton with kidney cysts | Cenani-Lenz syndactyly | Cenani-Lenz syndactyly, osteoporosis, Sclerosteosis | (102) |
| MEF2C | mef2ca | + | Ectopic bone formation of neural crest derived ligament due to altered DNA methylation | N/A | Unknown | (103, 104) |
| N/A | bone calcification slow | – | Non-mapped mutation causing delayed ossification and increased Cyp26b1 expression | N/A | N/A | (105) |
| PANX3 | panx3 MO | – | Altered Ca2+ channel activity reducing endochondral ossification | N/A | N/A | (106) |
| PLS3 | pls3 MO | – | Reduced larval operculum mineralization | Osteoporosis | X-linked osteoporosis | (107) |
| PTCH1, PTCH2 | ptc1 (ptc2), ptc2 (ptc1) | + | Increased mineralization in endochondral bone | N/A | Holoprosencephaly | (67) |
| PTH4 # | pth4* | – | Neuronal regulation of phosphate metabolism | N/A | PTH4 is absent in terrestrial animals | (109) |
| PTH+P / PTHLH / PTH3 | pthlh/pthlh MOs | + | Premature ossification during larval stage under control of sox9 | N/A | Brachydactyly; mutation in promoter | (109) |
| RANKL | rankl ¥ | – | Induces osteoclast activity | Osteoporosis | None–Teleost specific gene | (34) |
| RFP # | rapunzel | + | Increased BMD in craniofacial and spinal column elements | N/A | Decreased BMD; skeletal dysplasia | (111) |
| SLC10A7 | slc10a7 MO | – | Secretory pathway defect | N/A | Decreased BMD; skeletal dysplasia | (111) |
| SP7 (OSX, osterix) | sp7 (osx, osterix) | – | Decreased mineralization, skull sutures defects, impaired tooth formation, increased BMP signaling, and reduced differentiation, but increased proliferation, of osteoblasts. Homozygous mutant adults are viable | Osteogenesis imperfecta, osteoporosis (?) | Osteogenesis imperfecta | (112, 113) |
| SP7 (OSX, osterix) | sp7 (osx, osterix) ¥ | – | Decreased mineralization of endochondral bone and vertebrae. Reduced osteoblast number. Homozygous lethal at 14 dpf | Osteogenesis imperfecta | Osteogenesis imperfecta | (114, 115) |
| SPP1 | spp1 (osteopontin) $ | – | Reduced AR staining in 5 dpf craniofacial skeleton. Absent in whale shark genome | N/A | N/A | (116) |
| TGFβ3 | tgfβ3 MO | – | Reduced calcification of juvenile bone | N/A | Oral clefting | (117) |
| TSHR | opallus | + | Mutation causes a constitutive active Tshr leading to hyperthyroidism causing high BMD | Hyperthyroidism | Hyperthyroidism | (78) |
| TWIST and TCF12 | twist1b and tcf12 | +/- | Frontal skull sutures due to increased osteoblast proliferation. Mineralization normal. | Saethre-Chotzen syndrome | Saethre-Chotzen syndrome | (119) |

$Mosaicism; MO, Morpholino; ¥No clear ortholog; (?)Indicated / implied; *Transgene affecting gene; ¥Medaka.

misshapen bones. Moreover, rare craniofacial characteristics caused by impaired SP7 function, such as wormian bones, reported in human patients carrying mutations in SP7 were also observed in zebrafish (112).

Another example of a zebrafish mutant that recapitulates patient phenotype is the bmp1a mutant frilly fins (frf). In humans a damaging missense mutation in the BMP1 signal peptide causes brittle bones in an osteogenesis imperfecta pedigree (79). frf mutants showed normal osteoblast number, but pericellular pro-collagen processing (C-pro-peptide removal) defect leading to mineralization defects in the axial skeleton and fin rays (79).

Collagenopathies, such as Stickler Syndrome, have also been successfully modeled in zebrafish. We have recently reported a col11a2 zebrafish mutant showing specific traits of the human disease which include thicker collagen fibers and degradation of
Figure 4 | Fin regeneration and fracture assay to visualize and quantify live bone formation and repair. (A) Schematic representation of a zebrafish with a standard fluorescent stereomicroscope image of a live Alizarin red S (AR) pre-amputation caudal fin (inset). (B) Schematic representation of bone regeneration after fin amputation showing the (simplified) cascade of events that follow after fin amputation to regenerate bone (a single ray depicted here). This allows studying de novo bone formation by newly formed osteoblasts (orange cells) and differentiated osteoblasts (green cells) and subsequent remodeling by osteoblasts and osteoclasts (purple cells) in an adult fish. Note that during osteogenesis that there is a gradient of mineralization. (C) Live images of the tail fin labeled with Alizarin red (red) prior to amputation (i, ii) and Calcein (green) post-amputation (iii, iv) taken on a fluorescent dissecting microscope. All images in panel come from the same fish. Seven days post-amputation showing regrowth of new bone (green). Note that intense Calcein staining is visible distally from the amputation site (white dotted line). (D) The fracture healing assay involves applying pressure on a fin ray bone element to induce a small fracture to one segment of the fin ray (i), which is visible with live AR staining (ii). Green Calcein labels the new bone formed in the fracture callus by 7 days (ii and iv). The white arrow indicates the fracture site. Scale bars = 500 µm, 3 months old wildtype TL/EKK females.

type-II collagen in zebrafish larvae leading to compromised jaw shape, mechanical properties and movement of the jaw leading to premature OA (83). In many skeletal dysplasias zebrafish not only model the human condition but allow mechanistic insight into how genetic changes lead to the cellular changes that underpin the disease symptoms. As such zebrafish offer exciting prospects for delivering functional studies in new osteoporotic genetic loci.
ASSAYS OF CAUDAL FIN REGENERATION AND FRACTURE REPAIR TO ASSESS DE NOVO BONE MATRIX FORMATION

Zebrafish are capable of regeneration many tissues and organs including the heart, lens, and pancreas. They also show regeneration of skeletal tissues following amputation of the tail fin (lepidotrichia) or removal of elasmoid scales (126, 127). As the fins and scales are translucent, and readily imaged they allow cells and their calcified matrix to be visualized in detail using standard fluorescent microscopes (Figure 4A). After amputation of a ray fin (typically a caudal fin), a wound healing response results in the formation of an epimorphic blastema which regenerates all affected tissues of the amputated organ, including bone, in a controlled fashion (128). Following this inflammation response, osteoblasts undergo dedifferentiation and proliferate to
contribute to the blastema (33, 129). These juvenile osteoblasts then secrete matrix with intermediate properties between cartilage and bone and are later remodeled as mature bone by matured osteoblasts and recruited osteoclasts (Figure 4B) (33, 128). These fins can also be injured via cryo-injury by placing a −196°C knife perpendicularly to the caudal fin rays allowing to study the bone resorption response (130). These techniques offer great perspectives to compare bone formation and bone remodeling, in an adult context.

Using transgenic lines and in vivo staining methods, such as AR (fluoresces red, 545 nm excitation, 580 nm emission) and Calcein (fluoresces green, 495 nm excitation, 515 nm emission), which binds to calcified matrix, the dynamics of bone formation can be visualized by using a fluorescent stereomicroscope in a regenerating caudal fin of a living fish. This allows longitudinal analysis by following regeneration rate and volume, since AR stains fully mineralized bone and Calcein binds to newly deposited bone matrix (Figure 4C).

The utility of fin regeneration assays to test bioactive compounds has been demonstrated by treating regenerating fins with the glucocorticoid prednisolone. Following treatment bone formation was reduced, and furthermore, both osteoblast number and subsequent bone deposition and osteoclast recruitment was reduced in these fins (131). Interestingly, skull injury repair is less affected following prednisolone treatment (131), this is similar to mammals. Treatment of fins with Botulinum toxin (Botox) leads to a reduction in bone mineralization and regeneration following amputation (132), comparable to the situation in mammals where fracture repair is impaired following Botox induced paralysis (133, 134).

A major issue with OP is increased fracture risk due to weaker bone structure, and therefore identification of therapeutics that can improve fracture healing is desirable. Zebrafish show a fracture healing response, including callus formation (Figure 4D), with strong similarities to that of mammals. Fractures can be induced in zebrafish fins using simple pressure applied externally to the fin (131, 135). As the fin has around 300 bony rays, multiple fractures can be induced in a single fin. A fracture callus is formed and de novo bone formation is initiated 2 days post-injury accompanied by an increased expression of osteoblast genes such as runx2 and sp7/osx (131, 135). As the fin is flat, the fracture repair process can be dynamically tracked at cellular resolution using transgenic lines (Table 1) or by labeling bone formation with AR and Calcein (Figure 4D). As for regeneration, it is possible to add pharmacological agents to the regenerating tissue (131), allowing potential osteoanabolic compounds to be tested for beneficial effects in fracture repair in vivo (136).

**SKELETAL ASSAYS USING ELASMOID SCALES**

The body of zebrafish is covered with elasmoid scales made of calcified dermal bone harboring osteoblasts and osteoclasts (Figures 5A–C). The calcified matrix is composed of a plywood structure of collagen fibrils (137), which are easily visualized with second harmonics generation microscopy (Figure 5D). Scales are embedded in, and grow from, the dermis and shed and replace naturally throughout life of the fish (138). As scales are part of the exoskeleton they are easy to collect from an anesthetized fish. Each flat scale is subdivided in four regions by its morphology: anterior, lateral, central, and central with epidermis (Figure 5A) (139). The anterior region is attached to the skin and does not grow or form new bone. The lateral area is characterized by its curved ridges (circuli), whereas the central area has linear trenches. Within the lateral circuli and central grooves newly mineralized matrix is formed by osteoblasts (139) and degraded by osteoclasts (140). The posterior area has increased osteoblast number and bone is continuously deposited (Figures 5A,B). Osteoblasts in different regions of the scale express different markers of maturity (97). As the scale contains living cells, including nerve and vascular endothelial cells, their use offers an opportunity to study bone cell behavior in a mature context.

**PHARMACOLOGICAL MANIPULATION OF BONE TISSUE AND CHEMICAL GENETIC SCREENING**

As larvae are small and develop in water, it is possible to grow larvae in multi-well format with the addition of water-soluble compounds to their growth media for easy uptake. Zebrafish have been used extensively for high-throughput screening using larvae and now drugs are used in clinical studies that were first identified in zebrafish. A great example is the identification of the kinase inhibitor dorsomorphin (BMP type-1 receptor (BMP1R) antagonist) to treat lymphoma which was discovered in an early embryogenesis phenotype screen using 7,500 small-molecules (141, 142). Another example used semi-automated imaging strategy of Calcein stained larvae exposed to a small-compound library identifying 6 catabolic and 2 anabolic compounds that alter notochord mineralization (143) (Table 3). Thus, when fluorescent compounds are twinned with fluorescent reporters for osteoblasts (e.g., sp7/gfp with AR) (Figure 2B), it will allow assessment of osteoblast number and activity in a semi-high content setting using plate imaging microscopy (162). When these assays are combined with high efficiency CRISPR/Cas9 genome engineering strategies, it will open avenues to test compounds of interest that could alter disease causing mutations deteriorating effects. Thus, this comprehensive approach will also offer opportunities to develop compounds for personalized medicine. For OP research it may be more advantageous to focus on adult skeletal assays to allow assessment of osteoclast activity (bone catabolism) simultaneously with an assessment of osteoblasts (bone anabolism). An example of pharmaco-genetics improving brittle bones, is when type-I collagen secretion in the bone matrix is ameliorated by treating chi/+ mutants with 4 phenyl butyrate (4PBA) compound (86).

Zebrafish elasmoid scales are bony plates that are small and contain bioactive osteoblasts and osteoclasts (Figures 5B,C). These therefore offer huge potential as a primary pharmacological screening tool for skeletal compounds. The scales can be cultured for 72-h post-harvesting during which they...
| Treatment                      | Gene/pathway                          | BMD effect | Primary effect                                                                                   | Part of compound screen? | Life stage          | Citation |
|--------------------------------|----------------------------------------|------------|-----------------------------------------------------------------------------------------------|---------------------------|---------------------|----------|
| 4PBA                           | HSP47–ER protein/fibrillar collagen folding | +          | Increased mineralization in both WT and chi/+ fish due to better clearing of type-I collagen from ER | No                        | Adult larval        | (88)     |
| Alendronate / etidronate        | Alendronate/etidronate therapies (bisphosphonates) | +          | Counteracts the negative effects of GIOP on scales. Reduced TRAP and increased AL activities.       | No                        | Adult larval        | (144, 145) |
| BGL398                         | FGF-receptor kinase inhibitor          | –          | Reduced sp7 positive osteoblasts in elasmoid scales resulting in impaired scale growth            | No                        | Adult               | (92)     |
| BML-2832 library               | Alkaline phosphatase inhibitors        | +/-        | Six catabolic and two anabolic compounds affect larval mineralization of the vertebral region.       | Yes                       | Larval              | (143)    |
| BMP-2a                          | BMP pathway                           | +          | Increased sp7:luciferase activity on cultured scales                                             | No                        | Adult               | (38)     |
| Botulinum toxin                | Botox muscle paralyzes                 | –          | Lower BMD and bone deposition in fin ray bones due to muscle paralysis. Impaired osteoblast differentiation. | No                        | Adult               | (132)    |
| Cobalt chloride                | Down-regulation of stem cell markers   | –          | Reduced number of osteoblasts and subsequent mineralization of the operculum, without affecting its size. | No                        | Larval              | (146)    |
| Cyclopamine and BMS-833923     | Hedgehog pathway                      | –          | Smaller scales and fins during regeneration. Scales show a lower number of osteoblasts.           | No                        | Adult               | (97, 147) |
| Dexamethasone                   | Glucocorticoids                        | –          | Glucocorticoid pathway inducing osteoporosis (GIOP) by inhibiting osteoblast activity             | No                        | Adult larval        | (148)    |
| DMP-PYT                        | BMP–R–SMAD1/5/9                        | +          | Increased BMP (pSMAD1/5/8(9)) and WNT signaling in 6–7 dpf larvae exposed for 4 days.           | Yes, C2C12 cells         | Larval              | (149)    |
| Dorsomorphin                   | BMP–R–SMAD1/5/9                        | –          | Reduced BMP (pSMAD1/5/8(9)) and ALK activity, reducing osteogenesis by inhibiting osteoblast activity, | Yes, compound libraries  | Embryo larvae       | (141)    |
| Ferric ammonium citrate        | Radical Oxygen Species                 | –          | Iron overload down regulating osteogenic markers which can be rescued with hepcidin1 overexpression | No                        | Adult larval        | (150, 151)|
| High fat diet                  | Obesity risk factor for OP             | –          | Increased osteoclast activity in elasmoid scales                                               | No                        | Adult               | (152)    |
| High glucose diet              | Hyperglycemia OP risk factor           | –          | Increased osteoclast activity and peripheral bone degradation in elasmoid scales                | No                        | Adult               | (153)    |
| Hyper-gravity                  | Increased loading                      | +          | Enhanced mineralization after exposure to 3 g in a large diameter centrifuge                    | No                        | Larval              | (154)    |
| Niclosamide, Riluzole, Genistein| WNT pathway                           | +          | Increased sp7:luciferase activity on cultured scales                                             | Yes, WNT compound library | Adult larval        | (38)     |
| N-L-LEL and anandamide         | Long-chain fatty acids binding cannabimod type receptors | +          | Higher alkaline phosphatase activity and protecting effect on the alteration of bone markers induced by GIOP | Yes, on scales            | Adult               | (155)    |
| Oligosacharides                | A. bidentata oleosacharides            | +          | Dried root extract of Asian medicinal herb reducing osteoclast and increasing osteoblast activities | No                        | Larval              | (156)    |
| Omega-6 Arachidonic acid       | Omega-6 derivative                     | –          | Stimulating matrix metalloproteinase activity Enhanced bone turnover by increased osteoclast activity in the scale. | No                        | Adult               | (157)    |
| Prednisolone                   | Glucocorticoids                       | –          | Glucocorticoid pathway inducing osteoporosis by inhibiting osteoblast activity                   | Yes, used as OP control  | Adult larval        | (100, 140)|
| R115866                        | Cyp26 antagonist–retinoid acid metabolism | +          | Hyper-mineralization of axial skeleton and phenocopying of stocktaf mutant phenotype            | No                        | Larval              | (37)     |

(Continued)
TABLE 3 | Continued

| Treatment       | Gene/pathway                                                                 | BMD effect | Primary effect                                                                 | Part of compound screen? | Life stage | Citation |
|-----------------|-------------------------------------------------------------------------------|------------|--------------------------------------------------------------------------------|----------------------------|-----------|----------|
| Retinonic acid  | Cyp26b1 and collagen deposition                                                | +          | Altered collagen deposition due to increased activity of Cyp26b1               | No                         | Larval    | (37, 158) |
| RU486           | Glucocorticoid receptor antagonist                                             | +          | Used as prednisolone specificity/toxicity control—reverses its catabolic effect| No                         | Larval    | (145)    |
| SD-134          | Inhibits legumain (LGVM) protease domain                                       | +          | Increase in larval vertebrae mineralization after 4 days of exposure (7 dpf)   | No                         | Larval    | (101)    |
| Sodium           | Silicate ion                                                                  | +          | Silicate ion stimulating osteoblast function                                   | No                         | Larval    | (159)    |
| metasilicate    |                                                                                |            |                                                                                  |                            |           |          |
| SUS402          | FGF-1 receptor antagonist                                                      | –          | Impaired osteoblast proliferation in amputated fins                            | No                         | Adult     | (53)     |
| Swimming         | Bone loading                                                                  | +          | Zebrfish performed controlled exercise in a tunnel have a higher vertebrae BMD compared to non-exercising fish | No                         | Adult     | (160)    |
| exercise         |                                                                                |            |                                                                                  |                            |           |          |
| Tanshinol       | Dp(þ)b-3,4-dihydroxyphenyl lactic acid                                        | +          | Herbal extract reducing oxidative stress and reduction of glucocorticoid induced osteoporosis phenotype. | No                         | Larval    | (148)    |
| Teriparatide     | Teriparatide (parathyroid hormone)                                            | +          | Human osteoporosis treatment increases mineralization in GIOP fish.            | No                         | Larval    | (161)    |
| Vitamin D3      | Cholecalciferol and calcitriol                                                 | +          | Enhanced mineralization in prechordal sheet and cleithrum due to altered calcium uptake. | No                         | Larval    | (146, 161) |

can arrayed in multi-well plates and exposed to pharmacological compounds. As the scale is thin, osteoblasts are accessible to osteogenic factors, and have been demonstrated to react in a dose dependent manner to BMP-2 (38). To model an OP-like phenotype, individuals can easily be exposed to prednisolone / dexamethasone (glucocorticoid pathway) (140, 148), ferric ammonium citrate (150, 151), or metabolically with a high fat or glucose diet (152, 153), see also Table 3. In the context of glucocorticoid induced OP (GIOP), the bisphosphonate Alendronate reverses the effects of prednisolone on ex vivo cultured elasmoid scale bone, which showed a reduction in osteoclast activity (measured by TRAP) and an increase in bone anabolism (measured by alkaline phosphatase activity) (144); the same response as in mammals (163, 164). As fat metabolism has been implicated with OP, a small fatty acid derivative library was used on GIOP adult fish. Biochemical assays on scales derived from these fish showed that cannabinoid receptor 2 binding anandamide and N-linoleoylethanolamine (N-LLEL) fatty acids drive osteogenesis by stimulating alkaline phosphatase (ALK) activity (155).

A WNT-pathway compound library was tested to identify new osteo-anabolic compounds using an assay in which luciferase was expressed under control of the sp7 promoter allowing a quantitative readout of osteoblast activity (Figure 6). This screen identified three osteo-anabolic (Table 3) and 15 osteo-catabolic compounds from 85 trial compounds (38). This library contained five previously published compounds tested in vivo, and nine tested in vitro mammalian bone progenitor cell lines. Strikingly, this scale luciferase assay was able to reproduce the effect of all in vivo tested compounds and about half of all in vitro tested compounds (38). These studies demonstrate the exciting potential that scale assays represent for testing of skeletal compounds relevant to OP in a cost-effective manner.

**POTENTIAL DRUG DISCOVERY PIPELINE FOR OSTEOPOROSIS**

Recently, there has been a substantial expansion in the quantity of high-quality genetic data from large-scale human genomic and transcriptomic studies that contain potential osteo-anabolic factors. Here we describe a potential screening pipeline that makes use of the genetic tractability and imaging in zebrafish to offer a relatively low cost, high-throughput option compared to traditional in vitro and in vivo models (Figure 7).

After identification of several candidate genes/drug targets from human genetic studies, the pipeline consists of two experimental arms that can be carried out simultaneously to generate primary pre-clinical data to validate the putative drug targets. Using genome editing, loss-of-function studies can be performed in transgenic backgrounds to test the effect of the gene of interest on the developing skeleton or on mineralization, and simultaneously allowing safety testing for deleterious effects on other tissues or organs. For example, using CRISPR/Cas9 editing, it is possible to generate hundreds of mosaic zebrafish mutants within 3–4 weeks (includes the generation of the targeting reagents), which is difficult to achieve in other available systems, such as cultured chondrocytes and osteoblasts (differentiation of...
FIGURE 6 | Schematic representation to show how osteoblast activity can be quantified from scales, Scales from sp7: luciferase transgenic reporter fish are harvested from the lateral flanks of a fish, then cultured in multi-well plates with DMEM culture medium (orange wells) at 28°C for 24 h. Compounds of interest can then be added (red wells) to the scales and incubated prior addition of a luciferin cocktail (green wells) and measurement of luciferase activity with a luminescent (yellow sparks) plate reader. Based on text from de Vrieze et al. (38).

these takes multiple weeks). With CRISPR/Cas9 editing it is also feasible to study the specific human disease mutation in zebrafish, as long as it is in a conserved coding region. These fish can be grown to adulthood and germline mutations identified allowing more detailed studies on the mature skeleton to be performed (Figure 7).

In addition to genetic studies, pharmacological assessment of the identified putative drug target can be performed. By using water-soluble compounds, or lipid soluble compounds dissolved in DMSO, screens in a multi-well format can be performed using ex vivo culture of elasmoid scales. As a single adult fish has around 200 scales (138), this assay allows testing of many compounds, including control compounds (e.g., osteo-anabolic [alendronate] and -catabolic [prednisolone], on scales harvested from a single individual, reducing intra-individual variation (38). Therefore, this technique offers a platform to generate a primary read-out of novel osteo-active compounds in the context of homeostasis in a mature tissue. Additionally, this ex vivo technique will reduce the number of (potentially harmful) compounds being exposed to living fish, therefore contributing to ethical refinement and reduction of experimental animal use, but also reducing associated costs. As this scale assay reduces the number of putative osteogenic compounds substantially, these positive compounds can be further validated (along with safety testing) on developing transgenic larvae. These larvae would be plated out at 3 larvae per well and the compounds added from 3 days of development, with high-content imaging used for preliminary assessment of the effects of each compound and more detailed analysis including dose response followed up for validated positive hits. Further downstream tests, such as fin regeneration or fracture assays, can further reduce the number of compounds as such that only high-confidence compounds will be assessed in tetrapod pre-clinical studies (Figure 7).

If desired, the two experimental arms can be performed simultaneously, so that stable mutants are being generated during the compound testing phase. This opens the possibility to perform pharmacogenetic experiments in a relatively short time frame to validate the effects of putative drugs on specific disease mutations to see if they can “rescue” the disease phenotype (Figure 7). Together, zebrafish offer the potential in future to

Frontiers in Endocrinology | www.frontiersin.org 14 January 2019 | Volume 10 | Article 6
bridge the gap between human genetic hits, and fast functional validation.

PROSPECTS FOR ZEBRAFISH IN OSTEOPOROSIS RESEARCH

The zebrafish is a well-established increasingly used animal model for studying various diseases including (congenital) metabolic bone diseases (165). As zebrafish have historically been mainly used for its fast-embryonic development properties to better understand disease onset, zebrafish aging studies have only recently been conducted to model age-related diseases such as OA and OP. OP is an emerging field in zebrafish modeling and more research is needed to fully establish an OP-like phenotype as it was previously determined in its teleost cousin medaka (34). The advantageous properties as set-out in this review should be further exploited to benefit drug development for OP. Zebrafish show the appropriate response to increased mechanical loading, where the cellular (transcriptional) response initiates increased bone formation and mineralization in the loaded bone elements that are easily quantified (154, 160). However, since zebrafish and mammalian bone morphology show some differences (64), a pharmacological assay should particularly focus on the complex tissue and osteoblast-osteoclast interactions that underpin OP pathology. As traditional rodent and in vitro co-culture both have limitations to pursue large-scale drug discovery in a genetic context, zebrafish can take the place as a primary testing platform and therefore opening avenues to work toward gene specific compound discovery that have been identified as risk factors.
in human genetic studies. After primary safety testing, these identified compounds can be further tested in mammalian OP models to determine the effect on BMD, bone strength, and trabeculation. Fully exploiting these opportunities by using zebrafish as a primary screening model will open exciting avenues to perform pharmacogenetics for OP on a larger scale.

ETHICS STATEMENT

Zebrafish procedures were approved by the University of Bristol Animal Welfare and Ethical Review Body (AWERB) and performed in accordance with a UK Home Office project license.

AUTHOR CONTRIBUTIONS

DB and EK generated the figures for the manuscript. DB, EK, and CH researched and drafted the manuscript together.

REFERENCES

1. Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. (2013) 8:136. doi: 10.1007/s11657-013-0136-1
2. Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos. (2013) 8:137. doi: 10.1007/s11657-013-0137-0
3. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Regitn JA, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. (2013) 24:23–57. doi: 10.1007/s00198-012-2074-y
4. Baron R, Hesse E. Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab. (2012) 97:311–25. doi: 10.1210/jc.2011-2332
5. Garber K. Two pioneering osteoporosis drugs finally approach approval. Nat Rev Drug Discov. (2016) 15:445. doi: 10.1038/nrd.2016.132
6. Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. (2017) 5:898–907. doi: 10.1016/S2213-8587(17)30188-2
7. Metcalf LM, Aspray TJ, McCloskey EV. The effects of parathyroid hormone peptides on the peripheral skeleton of postmenopausal women. Syst Rev Bone (2017) 99:39–46. doi: 10.1016/j.bone.2017.03.007
8. Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M. Bone neoplasms in F344 rats Given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol. (2004) 32:426–38. doi: 10.1080/0192623049462138
9. Watanabe A, Yoneyama S, Nakajima M, Sato N, Takaor-Kawabata R, Isogai Y, et al. Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34)). J Toxicol Sci. (2012) 37:671–29. doi: 10.2131/jst.37.671
10. Ihitsina A, Fogelman I, Hampson G. Treatment of post-menopausal osteoporosis beyond bisphosphonates. J Endocrinol Invest. (2015) 38:13–29. doi: 10.1007/s40618-014-0152-2
11. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Diosoeg M, et al. Increased bone density in sclerosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. (2001) 10:537–43. doi: 10.1093/hmg/10.5.537
12. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. (2014) 370:412–20. doi: 10.1056/NEJMoa1305224
13. McClung MR. Romosozumab for the treatment of osteoporosis. Osteopor Sarcop. (2018) 4:11–5. doi: 10.1016/j.jafs.2018.03.002
14. Gregson CL, Steel SA, O’Rourke KP, Allan K, Ayuk J, Bhalla A, et al. ‘Sink or swim’: an evaluation of the clinical characteristics of individuals with high bone mass. Osteopor Int. (2012) 23:643–54. doi: 10.1007/s00198-011-1603-4
15. Gregson CL, Wheeler L, Hardcastle SA, Appleton LH, Addison KA, Brugmans M, et al. Mutations in known monogenic high bone mass loci only explain a small proportion of high bone mass cases. J Bone Min Res. (2016) 31:640–9. doi: 10.1002/jbmr.2706
16. Kemp JP, Morris IA, Medina-Gomez C, Forgetta V, Warrington NM, Youlton SE, et al. Identification of 153 new loci associated with heel bone mineral density and functional involvement of GPC6 in osteoporosis. Nat Genet. (2017) 49:1468–75. doi: 10.1038/ng.3949
17. Gregson CL, Newell F, Leo PJ, Clark GR, Paternoster L, Marshall M, et al. Genome-wide association study of extreme high bone mass: contribution of common genetic variation to extreme BMD phenotypes and potential novel BMD-associated genes. Bone (2018) 114:62–71. doi: 10.1016/j.bone.2018.06.001
18. Kim SK. Identification of 613 new loci associated with heel bone mineral density and a polygenic risk score for bone mineral density, osteoporosis and fracture. PLoS ONE (2018) 13:e0200785. doi: 10.1371/journal.pone.0200785
19. Morris JA, Kemp JP, Youlten SE, Laurent L, Logan JG, Chai R, et al. An atlas of human and murine genetic influences on osteoporosis. bioRxiv [preprint] (2018). doi: 10.1101/338863
20. Tachmazidou I, Hatzikotoulas K, Southam L, Espana-Gordillo J, Haberland V, Zheng J, et al. Identification of new therapeutic targets for osteoarthritis through genome-wide analyses of UK Biobank. bioRxiv [preprint] (2018). doi: 10.1101/455350
21. Sudlow C, Gallagher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. (2015) 12:e1001779. doi: 10.1371/journal.pmed.1001779
22. Cannon ME, Mohlke KL. Deciphering the emerging complexities of molecular mechanisms at GWAS loci. Am J Hum Genet. (2018) 103:637–53. doi: 10.1016/j.ajhg.2018.10.001
23. Mackay EW, Apschner A, Schulte-Merker S. A bone to pick with zebrafish. Bonekey Rep. (2015) 2:445–445. doi: 10.1038/bonekey.2015.179
24. Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. Stages of embryonic development of the zebrafish. Dev Dyn. (1995) 203:253–310. doi: 10.1002/aja.102030302
25. Howe K, Clark MD, Torroja CF, Torrance J, Berthelot C, Muñato M, et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature (2013) 496:498–503. doi: 10.1038/nature12111
26. Kettleborough RN, Busch-Nentwich EM, Harvey SA, Dooley CM, de Bruijn E, van Eeden F, et al. A systematic genome-wide analysis of zebrafish.

ACKNOWLEDGMENTS

We would like to thank the Wolfson Bioimaging Facility for confocal microscope (Leica SP5II) access and imaging support; in particular Katy Jepson for assistance with lightsheet (Zeiss Z1 lightsheet funded by the Wellcome Trust) imaging, and Dom Alhibi and Dr. Nicola Stevenson for assistance with SHG imaging (acquired on Leica SP8 AOBS CLSM with multiphoton lasers funded by the MRC). Faxitron is acknowledged for trialing the digital X-ray machine (Multifocus). We gratefully acknowledge Versus Arthritis (formerly known as Arthritis Research UK) for their funding of CH, EK, and DB (21211, 21937, 19476), and The Elizabeth Blackwell Institute for Health Research (University of Bristol) and the Wellcome Trust Institutional Strategic Support Fund for the postgraduate extension (discipline hopping) fellowship (204813/Z/16/Z) that funded DB.
protein-coding gene function. *Nature* (2013) 496:494–7. doi: 10.1038/nature11992

27. Bussmann J, Schulte-Merker S. Rapid BAC selection for tol2-mediated transgenesis in zebrafish. *Development* (2011) 138:4327–32. doi: 10.1242/dev.048380

28. Hammond CL, Moro E. Using transgenic reporters to visualize bone and cartilage signaling during development *in vivo*. *Front Endocrinol.* (2012) 3:91. doi: 10.3389/fendo.2012.00091

29. Mitchell RE, Huitema LF, Skinner RE, Brunt LH, Severn C, Schulte-Merker S, et al. New tools for studying osteoarthritis genetics in zebrafish. *Osteoarthr. Cartil.* (2013) 21:269–78. doi: 10.1016/j.joca.2012.11.004

30. Alexander C, Zuniga E, Blutis IL, Wada N, Le Pabic P, Javidan Y, et al. Catabolism induces two types of endochondral ossification, different types of osteoblast clusters and a new bone type. *Dev Cell* (2011) 20:713–24. doi: 10.1016/j.devcel.2011.04.014

31. Lawson ND, Weinstein BM. *In vivo* imaging of embryonic vascular development using transgenic zebrafish. *Dev Biol.* (2002) 248:307–18. doi: 10.1016/S0012-1606(02)01071-1

32. Schwend T, Loucks EJ, Ahlgren SC. Visualization of Gli activity in craniofacial tissues of hedgehog-pathway reporter transgenic zebrafish. *PLoS ONE* (2010) 5:e14396. doi: 10.1371/journal.pone.0014396

33. de Vrieze E, Zethof J, Schulte-Merker S, Flik G, Metz JR. Identification of Nodal signaling during development. *Development* (2011) 138:5135–46. doi: 10.1242/dev.067801

34. To TT, Witten PE, Renn J, Bhattacharya D, Huysseune A, Winkler C. Rankl-induced osteoclastogenesis leads to loss of mineralization in a medaka osteoporosis model. *Development* (2011) 138:141–50. doi: 10.1242/dev.071035

35. Wada N, Javidan Y, Nelson S, Carney TJ, Kelsh RN, Schilling TF. In vivo cartilage signaling during development. *Development* (2005) 132:3977–88. doi: 10.1242/dev.01943

36. DeLaurier A, Eames BF, Blanco-Sanchez B, Peng G, He X, Swartz ME, et al. Zebrafish sp7:EGFP: a transgenic for studying otic vesicle development using transgenic zebrafish. *Development* (2008) 135:3765–74. doi: 10.1242/dev.024034

37. Spooerdonck KM, Peterson-Maduro J, Renn J, Trowe T, Kranehnberg S, Winkler C, et al. Retinoic acid and Cyp26b1 are critical regulators of osteogenesis in the axial skeleton. *Development* (2008) 135:7657–74. doi: 10.1242/dev.024034

38. Singh SP, Holdway JE, Poss KD. Regeneration of amputated zebrafish fin rays from de novo assay. *Development* (2011) 138:511–9. doi: 10.1242/dev.01943

39. Singh SP, Holdway JE, Poss KD. Regeneration of amputated zebrafish fin rays from de novo osteoblasts. *Dev Cell* (2012) 22:879–86. doi: 10.1016/j.devcel.2012.03.006

40. To TT, Witten PE, Renn J, Bhattacharya D, Huysseune A, Winkler C. Rankl-induced osteoclastogenesis leads to loss of mineralization in a medaka osteoporosis model. *Development* (2011) 138:141–50. doi: 10.1242/dev.071035

41. Wada N, Javidan Y, Nelson S, Carney TJ, Kelsh RN, Schilling TF. Hedgehog signaling is required for cranial neural crest morphogenesis and chordogenesis at the midline in the zebrafish skull. *Development* (2005) 132:3977–88. doi: 10.1242/dev.01943

42. Le Pabic P, Javidan Y, et al. The identification of genes with unique and essential functions in the zebrafish genome editing using a high-efficiency TALEN system. *Nucleic Acids Res.* (2013) 41:607–16. doi: 10.1093/nar/gkt785

43. Rossi A, Kontarakis Z, Gerri C, Nolte H, Holper S, Kruger M, et al. Genetic compensation induced by deleterious mutations but not gene knockdowns. *Nature* (2015) 524:230–3. doi: 10.1038/nature14580

44. Cerikan B, Shaheen R, Colo GP, Gläßer C, Hata S, Knebelcho K-P, et al. Cell-intrinsic adaptation arising from chronic ablation of a key Rho GTase regulator. *Dev Cell* (2016) 39:28–43. doi: 10.1016/j.devcel.2016.08.020

45. Bergen DJM, Stevenson NL, Skinner REH, Stephens DJ, Hammond CL. The Golgi matrix protein giantin is required for normal cilia function in zebrafish. *Biol Open* (2017) 6:1186–90. doi: 10.1242/bio.025502

46. Gao Y, Zhang Y, Zhang D, Dai X, Estelle M, Zhao Y. Auxin binding protein 1 (ABP1) is not required for either auxin signaling or Arabidopsis development. *Proc Natl Acad Sci USA.* (2015) 112:2275–80. doi: 10.1073/pnas.1300365112

47. Rossi A, Kontarakis Z, Gerri C, Nolte H, Holper S, Kruger M, et al. Genetic compensation induced by deleterious mutations but not gene knockdowns. *Nature* (2015) 524:230–3. doi: 10.1038/nature14580
67. Hammond CL, Schulte-Merker S. Two populations of endochondral osteoblasts with differential sensitivity to Hedgehog signalling. Development (2009) 136:3991–4000. doi: 10.1242/dev.042150
68. Borovina A, Superna S, Vokas D, Ciruna B, Vang2 directs the posterior titling and asymmetric localization of motile primary cilia. Nat Cell Biol. (2010) 12:807–12. doi: 10.1038/ncb2042
69. Bird NC, Maibe PM. Developmental morphology of the axial skeleton of the zebrafish, Danio rerio (Ostariophysi: Cyprinidae). Dev Dyn. (2003) 228:337–57. doi: 10.1002/dvdy.10387
70. Fisher S, Jagadeeswaran P, Halpern ME. Radiographic analysis of zebrafish skeletal defects. Dev Biol. (2003) 264:64–76. doi: 10.1016/S0012-1606(03)00399-3
71. Andreeva V, Connolly MH, Stewart-Swift C, Fraher D, Burt J, Cardarelli J, et al. Identification of adult mineralized tissue zebrafish mutants. Genesis (2011) 49:360–6. doi: 10.1002/dvg.20712
72. Charles JF, Sury M, Tsang K, Urso K, Halpern ME. Radiographic analysis of zebrafish jawbone regeneration. Dev Biol. (2016) 12:307–20. doi: 10.1016/j.ydbio.2018.03.005
73. Asharani PV, Keupp K, Semler O, Wang W, Li Y, Thiele H, et al. 
74. Bowen ME, Henke K, Siegfried KR, Warman ML, Harris MP. 
75. Herbomel P, Thisse B, Thisse C. Zebrafish early macrophages colonize cephalic mesenchyme and developing brain, retina, and epidermis through hedgehog activation of MMP9 and MMP13. Development (2015) 142:1095–101. doi: 10.1242/dev.113811
76. Barsh GS, Zhang Y, Huang H, Zhao G, Yokoyama T, Vega H, et al. Developmental morphology of the axial skeleton of the zebrafish, Danio rerio (Ostariophysi: Cyprinidae). Dev Dyn. (2011) 88:54–62. doi: 10.1002/dvdy.20701
77. Mackay EW, Apschner A, Schulte-Merker S. Vitamin K reduces hypermineralisation in zebrafish models of PXE and GACI. Bone (2003) 29:385–9. doi: 10.1016/S0012-1606(03)00399-3
78. Hammond CL, Schulte-Merker S. Two populations of endochondral osteoblasts with differential sensitivity to Hedgehog signalling. Development (2009) 136:3991–4000. doi: 10.1242/dev.042150
79. Fiedler IAK, Schmidt FN, Wößel EM, Plummer C, Milovanovic P, Gioia R, et al. Severely impaired bone material quality in chihuahua zebras resembles classical dominant human osteogenesis imperfecta. J Bone Miner Res. (2018) 33:1489–99. doi: 10.1002/jbmr.3445
80. Gistelinck C, Kwon RY, Malefai F, Symoens S, Harris MP, Henke K, et al. Zebrafish type I collagen mutants faithfully recapitulate human type I collagenopathies. Proc Natl Acad Sci USA. (2018) 115:E8037–46. doi: 10.1073/pnas.1722001115
81. Tian J, Shao J, Liu C, Hou H-Y, Chou C-W, Shboul M, et al. Deficiency of lamp1 in zebrafish and human LRPS mutation induce aberrant activation of Jagged–Notch signaling in in vivo and limb development. Cell Mol Life Sci. (2019): 76:163–78. doi: 10.1007/s00018-018-2928-3
82. DeLaurier A, Huycke TR, Nichols JT, Swartz ME, Larsen A, Walker C, et al. Role of mef2ca in developmental buffering of the}

Frontiers in Endocrinology | www.frontiersin.org 18 January 2019 | Volume 10 | Article 6

Bergen et al. Zebrafish Osteoporosis

Bergen et al. Zebrafish Osteoporosis
zebrafish larval hyoid dermal skeleton. *Dev Biol.* (2014) 385:189–99. doi: 10.1016/j.ydbio.2013.11.016

104. Nichols JT, Blanco-Sanchez B, Brooks EP, Parthasarathy R, Dowd J, Subramanian A, et al. Ligament versus bone cell identity in the zebrafish hyoid skeleton is regulated by met2ca. *Development* (2016) 143:4430–40. doi: 10.1242/dev.110536

105. Xi Y, Chen D, Sun L, Li Y, Li L. Characterization of zebrafish mutants with defects in bone calcification during development. *Biochem Biophys Res Commun.* (2013) 440:132–6. doi: 10.1016/j.bbrc.2013.09.043

106. Oh SK, Shin JO, Baek JJ, Lee J, Bae JW, Ankamreddy H, et al. Pannexin 3 is required for normal progression of skeletal development in vertebrates. *FASEB J.* (2015) 29:4473–84. doi: 10.1096/fj.15-273722

107. van Dijk FS, Zillikens MC, Michi D, Risselmann M, Marcelis CLM, de Diesmullers CE, et al. PL3 mutations in linked osteoporosis with fractures. *N Engl J Med.* (2013) 369:1529–36. doi: 10.1056/NEJMoa1308223

108. Suarez-Bregua P, Torres-Nuñez E, Saxena A, Guerreiro P, Brashch I, Prober DA, et al. Pth4, an ancient parathyroid hormone lost in eutherian mammals, reveals a new brain-to-bone signaling pathway. *FASEB J.* (2017) 31:569–83. doi: 10.1096/fj.20160815R

109. Yan Y-L, Bhattacharya P, He XJ, Ponugoti B, Marquardt B, Layman J, et al. Duplicated zebrafish co-orthologs of parathyroid hormone-related peptide (PTHrP, Pthh) play different roles in craniofacial skeletogenesis. *J Endocrinol.* (2012) 214:421–35. doi: 10.1530/JOE-12-0110

110. Green J, Taylor JJ, Hindes A, Johnson SL, Goldsmith ML. A gain of function mutation causing skeletal overgrowth in the rapunzel mutant. *Dev Biol.* (2009) 334:224–34. doi: 10.1016/j.ydbio.2009.07.025

111. Ashikov A, Abu Bakar N, Wen X-Y, Niemeijer M, Rodrigues Osorio G, Brand-Arzamendi K, et al. Integrating glycomics and genomics uncovers SLCO1A7 as essential factor for bone mineralization by regulating post-Golgi protein transport and glycosylation. *Hum Mol Genet.* (2018) 27:3029–45. doi: 10.1093/hmg/ddy213

112. Kague E, Roy P, Asselin G, Hu G, Simonet J, Stanley A, et al. Osterix/Sp7 gene is required for maturation of osteoblast-lineage cells in medaka Oryzias latipes. *J Mol Histol.* (2014) 505:174–9. doi: 10.1038/nature12826

113. Zylberberg L, Bereiter-Hahn J, Sire JY. Cytoskeletal organization and chondrogenesis and osteogenesis in zebrafish is mediated through formation of extracellular matrix macromolecules: insights from vertebrate model systems. *Dev Dyn.* (2018) 237:329–44. doi: 10.1002/jb.25964

114. Pasqualetti S, Banfi G, Mariotti M. The zebrafish scale as model to study functional and survival of a subpopulation of the cranial neural crest. *Clin Cases Miner Bone Metabol.* (2015) 12:188–94. doi: 10.11138/ccmb/2015.12.2.188

115. Geurtzen K, Galatz LM, Patel N, Das R, Thomopoulos S. Recovery potential after postnatal shoulder paralysis. *J Bone Joint Surg. Am Vol.* (2009) 91.A:879–91. doi: 10.2106/JBJS.H.00088

116. Hao Y, Ma Y, Wang X, Jin F, Ge S. Short-term muscle atrophy caused by botulinum toxin-A: Local injection impairs fracture healing in the rat femur. *J Orthop Res.* (2012) 30:574–80. doi: 10.1002/jor.21553

117. Geurtzen K, Vernet A, Freidin A, Rauner M, Hofbauer LC, Schneider JE, et al. Immune suppressive and bone inhibitory effects of prednisolone in growing and regenerating zebrafish tissues. *J Bone Miner Res.* (2017) 32:2476–88. doi: 10.1002/jbmr.3231

118. Yu T, Graf M, Renn J, Scharlt M, Larianova D, Huysseune A, et al. A vertebrate-specific and essential role for osterix in osteogenesis revealed by gene knockdown in the teleost medaka. *Development.* (2017) 144:265–71. doi: 10.1242/dev.139550

119. Venkatesh B, Lee AP, Ravi V, Maurya AK, Lian MM, Swanb JR, et al. Elephant shark genome provides unique insights into gnathostome evolution. *Nature* (2014) 505:174–9. doi: 10.1038/nature12826

120. Cheah FS, Winkler C, Jabs EW, Chong SS. Tgbeta3 regulation of chondrogenesis and osteogenesis in zebrafish is mediated through formation and survival of a subpopulation of the cranial neural crest. *Mech Dev.* (2010) 127:329–44. doi: 10.1016/j.mod.2010.04.003

121. Teng CS, Ting MC, Farmer DT, Brockop M, Maxson RE, Crump JG. Altered bone growth dynamics prefigure craniosynostosis in a zebrafish model of Saethre-Chotzen syndrome. *Elife* (2018) 7:37024. doi: 10.7554/eLife.37024

122. Bella J, Liu J, Kramer R, Brodsky B, Berman HM. Conformational effects of Gly-X-Gly interruptions in the collagen triple helix. *J Mol Biol.* (2006) 362:298–311. doi: 10.1016/j.jmb.2006.07.014

123. Eyre DR, Weis MA. Bone collagen: new clues to its mineralization mechanism from recessive osteogenesis imperfecta. *Calcif Tissue Int.* (2013) 93:338–47. doi: 10.1007/s00223-013-9723-9

124. de Vrieze E, van Kessel MAH, Peters HM, Spanings FAT, Flik G, Metz JR. Prednisolone induces osteoporosis-like phenotype in regenerating zebrafish scales. *Osteoporos Int.* (2014) 25:567–78. doi: 10.1007/s00198-013-2441-3

125. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Huyng SA, et al. Dorosomorphin inhibits BMP signals required for embryogenesis and iron metabolism. *Nat Chem Biol.* (2008) 4:33–41. doi: 10.1038/nchembio.2007.54

126. Kithcart A, MacRae CA. Using zebrafish for high-throughput screening of novel cardiovascular drugs. *JACC Basic Transl Sci.* (2017) 2:1–12. doi: 10.1016/j.jatbs.2017.01.004

127. Chen JR, Lai YH, Tsai JL, Hsiao CD. Live fluorescent staining platform for drug-screening and mechanism-analysis in zebrafish for bone mineralization. *Molecules* (2017) 22:12. doi: 10.3390/molecules2212068
144. Pasqualetti S, Congiu T, Banfi G, Mariotti M. Alendronate rescued osteoporotic phenotype in a model of glucocorticoid-induced osteoporosis in adult zebrafish scale. *Int J Exp Pathol.* (2015) 96:11–20. doi: 10.1111/ijep.12106

145. Barrett R, Chappell C, Quick M, Fleming A. A rapid, high content, in vivo model of glucocorticoid-induced osteoporosis. *Biotechnol J.* (2006) 1:651–5. doi: 10.1002/biot.200600043

146. Tarasco M, Laize V, Cardeira J, Cancela ML, Gavaia PJ. The zebrafish operculum: a powerful system to assess osteogenic bioactivities of molecules with pharmacological and toxicological relevance. *Comp Biochem Physiol C Toxicol Pharmacol.* (2017) 197:45–52. doi: 10.1016/j.cbpc.2017.04.006

147. Armstrong BE, Henner A, Stewart S, Stankunas K. Shh promotes direct interactions between epidermal cells and osteoblast progenitors to shape regenerated zebrafish bone. *Development* (2017) 144:1165–76. doi: 10.1242/dev.143792

148. Luo S, Yang Y, Chen J, Zhong Z, Huang H, Zhang J, et al. Tanshinol stimulates bone formation and attenuates dexamethasone-induced inhibition of osteogenesis in larval zebrafish. *J Orthop Surg Res.* (2016) 4:35–45. doi: 10.1186/s13078-015-0404-3

149. Bae SJ, Kim HJ, Won HY, Min YK, Hwang ES. Acceleration of osteoblast differentiation by a novel osteogenic compound, DMP-PYT, through activation of both the BMP and Wnt pathways. *Sci Rep.* (2017) 7:8455. doi: 10.1038/s41598-017-08190-9

150. Chen B, Yan Y-L, Liu C, Bo L, Li G-F, Wang H, et al. Therapeutic effect of deferoxamine on iron overload-induced inhibition of osteogenesis in a zebrafish model. *Calcif Tissue Int.* (2014) 94:353–60. doi: 10.1007/s00223-013-9817-4

151. Zhang W, Xu J, Qiu J, Xing C, Li X, Leng B, et al. Novel and rapid osteoporosis model established in zebrafish using high iron stress. *Biochem Biophys Res Commun.* (2018) 496:654–60. doi: 10.1016/j.bbrc.2017.12.172

152. Carnovali M, Luzi L, Turruzzi I, Banfi G, Mariotti M. Metabolic and bone effects of high-fat diet in adult zebrafish. *Endocrine* (2017) 61:317–26.

153. Carnovali M, Luzi L, Banfi G, Mariotti M. Chronic hyperglycemia affects bone metabolism in adult zebrafish scale model. *Endocrine* (2016) 54:808–17. doi: 10.1007/s12020-016-1106-3

154. Aceto I, Nourizadeh-Lillabadi R, Maree R, Dardenne N, Jeannay N, Wehenkel L, et al. Zebrafish bone and general physiology are differently affected by hormones or changes in gravity. *PLoS ONE* (2015) 10:e0126928. doi: 10.1371/journal.pone.0126928

155. Carnovali M, Ottria R, Pasqualetti S, Banfi G, Ciuffreda P, Mariotti M. Effects of bioactive fatty acid amide derivatives in zebrafish scale model of bone metabolism and disease. *Pharmacol Res.* (2016) 104:1–8. doi: 10.1016/j.phrs.2015.12.009

156. Zhang S, Zhang Q, Zhang D, Wang C, Yan C. Anti-osteoporosis activity of a novel Achyranthes bidentata polysaccharide via stimulating bone formation. *Carbohydr Polym.* (2018) 184:288–98. doi: 10.1016/j.carbpol.2017.12.070

157. de Vrieze E, Moreen M, Metz JR, Flik G, Lie KK. Arachidonic acid enhances turnover of the dermal skeleton: studies on zebrafish scales. *PLoS ONE* (2014) 9:e89347. doi: 10.1371/journal.pone.0089347

158. Pogoda HM, Riedl-Quinkertz I, Lörh H, Waxman JS, Dale RM, Topczewski J, et al. Direct activation of chondroblasts by retinoic acid is required for segmented centra mineralization during zebrafish spine development. *Development* (2018) 145:9. doi: 10.1242/dev.159418

159. Montazerolghaem M, Nyström L, Engqvist H, Karlsson Ott M. Zebrafish: a possible tool to evaluate bioactive ions. *Acta Biomater.* (2015) 19:10–4. doi: 10.1016/j.actbio.2015.03.010

160. Suniaga S, Rolvien T, vom Scheidt A, Knapik JW, Huyseuse A, et al. Increased mechanical loading through controlled swimming exercise induces bone formation and mineralization in adult zebrafish. *Sci Rep.* (2018) 8:3646. doi: 10.1038/s41598-018-21776-1

161. Fleming A, Sato M, Goldsmith P. High-throughput in vivo screening for bone anabolic compounds with zebrafish. *J Biomed Screen.* (2005) 10:823–31. doi: 10.1177/1087057105279952

162. Wiley DS, Redfield SE, Zon LI. Chemical screening in zebrafish for novel biological and therapeutic discovery. *Methods Cell Biol.* (2017) 138:651–79. doi: 10.1016/bse.mcb.2016.10.004

163. Hassler N, Gamsjaeger S, Hofstetter B, Brozek W, Klaushofer K, Paschalis EP. Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties. *Osteopor Int.* (2014) 26:339–52. doi: 10.1007/s00198-014-2929-5

164. Ma X, Xu Z, Ding S, Yi G, Wang Q. Alendronate promotes osteoblast differentiation and bone formation in ovariectomy-induced osteoporosis through interferon-β/signal transducer and activator of transcription 1 pathway. *Exp Ther Med.* (2017) 15:182–90. doi: 10.3892/etm.2017.5381

165. Ludeman LN, Unlu G, Knapik EW. Zebrafish developmental models of skeletal diseases. *Curr Top Dev Biol.* (2017) 124:81–124. doi: 10.1016/bs.ctdb.2016.11.004

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Bergen, Kague and Hammond. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.